You are here

Research Development

Research & Development

Lung Biotechnology is building further on its foundation in PAH

A single isomer prostacyclin analogue oral tablet, Beraprost 314d modified release (BPS-314d-MR), is currently under Phase 3 clinical development.

The lung perfusion program is focused on making more viable lungs available for transplantation by using innovative techniques to improve their performance in vivo.

XenoLung seeks to increase access to and improve outcomes after lung transplantation for people with PAH and other fatal lung diseases.